Mesothelioma is a rare cancer that occurs almost as a whole caused by exposure to asbestos. Because there is no cure for this disease, life expectancy for most mesothelioma patients ranged between four and 18 months after diagnosis of mesothelioma is known for sure. Although there is no cure to date, some patients who are diagnosed early mesothelioma can be given a combination of aggressive therapy, like surgery, chemotherapy and radiation. Combination therapy, known as multimodality therapy, currently has the best chance to extend the life of the patient.
Study authors explain, "Gene methylation causes the development of malignant tumors in several tumor [malignant mesothelioma] are histologically divided into three subtypes, namely, epithelioid, sarcomatoid, and biphasic type, and it shows that mesothelin expression is restricted to types of epithelioid and biphasic epithelioid component MM type (malignant mesothelioma). However, the mechanism of expression regulation has not been clarified. "
A total of 118 lung specimens examined, including 39 MM, 41 lung carcinomas, 26 nonneoplastic lung lesions, and 12 samples of normal lung tissue. Specimens were tested for mesothelin expression by immunohistochemistry test, together with the methylation status of 20 locations mesothelin gene promoter.
The results showed mesothelin is expressed in the epithelioid subtype of epithelioid and biphasic subtypes. However, the expression of mesothelin is not found either in the sarcomatoid subtype and sarcomatous part of the biphasic type. Mesothelin gene promoter is significantly experienced hypomethylasi mesotehelioma malignant specimens without subtype when compared with other lung lesions and samples of normal lung tissue.
 |
| advanced cancer |
Post a Comment